| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 1.604.a | Amgros I/S | Viatris ApS, Sandoz A/S, Abcur AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Krka Sverige AB, Glenmark Pharmaceuticals Nordic AB, Teva Denmark A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Abacus Medicine A/S, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Otsuka Pharma Scandinavia AB, Macure Pharma ApS, Macure Pharma ApS, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Neuraxpharm Sweden AB, Orifarm A/S | 284.601.687 kr. | 25. oktober 2026 |
| Amgros 2027 2.212.a | Amgros I/S | Orion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB | 33.641.330 kr. | 13. oktober 2026 |
| Amgros 2027 2.212.a | Amgros I/S | Orion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB | 33.641.330 kr. | 13. oktober 2026 |
| Amgros 2027 2.212.a | Amgros I/S | Orion Pharma A/S, Orion Pharma A/S, 2care4 ApS, Teva Denmark A/S, Teva Denmark A/S, 2care4 ApS, Abacus Medicine A/S, Abacus Medicine A/S, 2care4 ApS, Chiesi Pharma AB, Orion Pharma A/S, Orion Pharma A/S, Paranova Danmark A/S, 2care4 ApS, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB, Glenmark Pharmaceuticals Nordic AB | 33.641.330 kr. | 13. oktober 2026 |
| Amgros 2027 1.1203.a | Amgros I/S | Navamedic AB, Hameln Pharma ApS, Macure Pharma ApS, Hameln Pharma ApS, Orifarm A/S, 2care4 ApS, Viatris ApS, Glenmark Pharmaceuticals Nordic AB, Øresund Pharma ApS, Sandoz A/S, Orifarm A/S, Paranova Danmark A/S, Vingmed A/S, Abacus Medicine A/S, Paranova Danmark A/S | 148.085.649 kr. | 13. oktober 2026 |